menu
    • menu
    [{"orgOrder":0,"company":"Beersheva Mental Health Center","sponsor":"Sha'ar Menashe Mental Health Center | Tirat Carmel Mental Health Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Pyridoxine Hydrochloride","moa":"Aromatic-L-amino-acid decarboxylase; Pyridoxal kinase","graph1":"Neurology","graph2":"Phase III","graph3":"Beersheva Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beersheva Mental Health Center \/ Sha'ar Menashe Mental Health Center | Tirat Carmel Mental Health Center","highestDevelopmentStatusID":"10","companyTruncated":"Beersheva Mental Health Center \/ Sha'ar Menashe Mental Health Center | Tirat Carmel Mental Health Center"},{"orgOrder":0,"company":"Wellbeam Consumer Health","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Acquisition","leadProduct":"Arnica Montana","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Wellbeam Consumer Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Cream","sponsorNew":"Wellbeam Consumer Health \/ Carlin Consumer Health","highestDevelopmentStatusID":"15","companyTruncated":"Wellbeam Consumer Health \/ Carlin Consumer Health"},{"orgOrder":0,"company":"Harvard School of Public Health (HSPH)","sponsor":"University of Toronto | Unity Health Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Pyridoxine Hydrochloride","moa":"Aromatic-L-amino-acid decarboxylase (DDC)||Vitamin B6 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Harvard School of Public Health (HSPH)","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard School of Public Health (HSPH) \/ University of Toronto | Unity Health Toronto","highestDevelopmentStatusID":"6","companyTruncated":"Harvard School of Public Health (HSPH) \/ University of Toronto | Unity Health Toronto"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Qatar University | Heidelberg University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"QATAR","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Pyridoxine Hydrochloride","moa":"Vitamin B6 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Qatar University | Heidelberg University","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Qatar University | Heidelberg University"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Pyridoxine Hydrochloride","moa":"Vitamin B6 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Analog Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Doxylamine Succinate","moa":"||Histamine H1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Analog Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Analog Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Analog Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Pyridoxine Hydrochloride

    Menu

    Pyridoxine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Analog Pharma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Analog Pharma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxylamine Succinate,Pyridoxine Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Analog Pharma Canada Launches its First Product on the Canadian Market

                            Details : PrALOG-Doxylamine/Pyridoxine is a combination of Doxylamine succinate (an antihistamine) and pyridoxine hydrochloride (vitamin B6) provide anti-nauseant and antiemetic activity.

                            Product Name : PrALOG

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 09, 2025

                            Lead Product(s) : Doxylamine Succinate,Pyridoxine Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Wellbeam Consumer Health

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Wellbeam Consumer Health

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arnica Montana,Dimethyl Sulfone,Pyridoxine Hydrochloride

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Carlin Consumer Health

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Carlin Consumer Health Acquires Penetrex from Wellbeam Consumer Health

                            Details : Through the acquisition, Carlin expands its OTC portfolio with Penetrex, a formulation using natural ingredients like Arnica and Vitamin B6 for joint and muscle pain.

                            Product Name : Penetrex

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Arnica Montana,Dimethyl Sulfone,Pyridoxine Hydrochloride

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Carlin Consumer Health

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Beersheva Mental Health Center

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Beersheva Mental Health Center

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyridoxine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Sha'ar Menashe Mental Health Center | Tirat Carmel Mental Health Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pyridoxal Kinase Activity in Tardive Dyskinesia

                            Details : Pyridoxine is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tardive Dyskinesia.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            July 25, 2013

                            Lead Product(s) : Pyridoxine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Sha'ar Menashe Mental Health Center | Tirat Carmel Mental Health Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Harvard School of Public Health (HSPH)

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Harvard School of Public Health (HSPH)

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyridoxine Hydrochloride

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : University of Toronto | Unity Health Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Air Pollution, Epigenetics and Cardiovascular Health: A Human Intervention Trial

                            Details : Vitamin B6 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Inflammation.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            May 30, 2013

                            Lead Product(s) : Pyridoxine Hydrochloride

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : University of Toronto | Unity Health Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EMS

                            Brazil arrow
                            OTS 2025
                            Not Confirmed

                            EMS

                            Brazil arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyridoxine Hydrochloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Tolerability of Apevitin BC Comparing to Vitamin Complex in Stimulating the Appetite

                            Details : Apevitin BC (Pyridoxine HCl) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anorexia.

                            Product Name : Apevitin BC

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 26, 2011

                            Lead Product(s) : Pyridoxine Hydrochloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hamad Medical Corporation

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Hamad Medical Corporation

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyridoxine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Qatar University | Heidelberg University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Early Nutritional Intervention in Patients With Autism Spectrum Disorders

                            Details : Pyridoxine HCl is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Autism Spectrum Disorder.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 29, 2010

                            Lead Product(s) : Pyridoxine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Qatar University | Heidelberg University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth